24 completed. 24 Phase 2, 5 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 24 | Completed 24 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 3 | Completed 3 |
Follow Coronavirus: new trials by email Literature Review of Coronavirus trials Research Report on Coronavirus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPI-1005 Treatment in Severe COVID-19 Patients Ebselen, Placebo - Covid19, Coronavirus | Phase 2 | Completed | Sound Pharmaceuticals, Incorporated | 25 | 2021-08-27 | 2026-06-29 |
| Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS Umbilical Cord Lining Stem Cells (ULSC), Placebo (carrier control) - Covid19, Corona Virus Infection | Phase 1 / Phase 2 | Completed | Restem, LLC. | 17 | 2020-12-23 | 2024-04-09 |
| NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis Soterix taVNS model 0125-LTE Stimulator - Active-Active Group, Soterix taVNS model 0125-LTE Stimulator - Sham-Active Group - Coronavirus, Covid19 | Phase 2 | Completed | Medical University of South Carolina | 13 | 2020-11-19 | 2022-07-26 |
| Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19 Rayaldee, Placebo - COVID-19, Coronavirus | Phase 2 | Completed | OPKO Health, Inc. | 171 | 2020-11-02 | 2024-05-28 |
| Inflammatory Signal Inhibitors for COVID-19 (MATIS) Ruxolitinib, Fostamatinib, Standard of care - Coronavirus, Covid19 | Phase 1 / Phase 2 | Completed | Imperial College London | 185 | 2020-10-02 | 2025-11-18 |
| A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19 CVnCoV 6 μg, CVnCoV 12 μg, Hepatitis A vaccine - Coronavirus, Covid19 | Phase 2 | Completed | CureVac | 668 | 2020-09-21 | 2023-09-28 |
| ACTIV-2: A Study for Outpatients With COVID-19 bamlanivimab 7000mg, BRII-196+BRII-198, AZD7442 (IV) - Coronavirus, Covid19 | Phase 2 / Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 4044 | 2020-08-19 | 2024-08-02 |
| Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study Plasma, Standard Therapy - Coronavirus, Coronavirus Infection | Phase 2 / Phase 3 | Completed | Universidad del Rosario | 92 | 2020-08-08 | 2020-11-27 |
| A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Hydroxychloroquine, Vitamin C, Vitamin D - COVID-19, Coronavirus Infection | Phase 2 | Completed | ProgenaBiome | 254 | 2020-06-22 | 2025-06-05 |
| Convalescent Plasma to Stem Coronavirus (CSSC-001) Anti- SARS-CoV-2 Plasma, SARS-CoV-2 non-immune Plasma - Coronavirus, Convalescence | Phase 2 | Completed | Johns Hopkins University | 180 | 2020-06-10 | 2022-04-26 |
| Effects of Early Use of Nitazoxanide in Patients With COVID-19 Nitazoxanide, Placebo - Covid19, Coronavirus | Phase 2 | Completed | Universidade Federal do Rio de Janeiro | 392 | 2020-06-08 | 2020-11-03 |
| A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19 APL-9, Vehicle Control - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Apellis Pharmaceuticals, Inc. | 72 | 2020-05-28 | 2022-03-23 |
| Investigating a Vaccine Against COVID-19 ChAdOx1 nCoV-19 (Abs 260), MenACWY vaccine, ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost - Coronavirus | Phase 2 / Phase 3 | Completed | University of Oxford | 10811 | 2020-05-28 | 2025-09-03 |
| Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells Allogenic pooled olfactory mucosa-derived mesenchymal stem cells, Standard treatment according to the Clinical protocols - COVID, Covid-19 | Phase 1 / Phase 2 | Completed | Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | 32 | 2020-05-11 | 2021-08-23 |
| A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19 ArtemiC, Placebo - COVID-19, Corona Virus Infection | Phase 2 | Completed | MGC Pharmaceuticals d.o.o | 50 | 2020-05-08 | 2021-08-31 |
| A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection Convalescent Plasma - Coronavirus, COVID-19 | Phase 2 | Completed | TriHealth Inc. | 159 | 2020-05-05 | 2021-12-07 |
| Convalescent Plasma for Patients With COVID-19 Convalescent plasma - Coronavirus Infection, Coronavirus | Phase 2 | Completed | Henry Ford Health System | 30 | 2020-05-04 | 2022-05-02 |
| Convalescent Plasma for Patients With COVID-19: A Pilot Study Plasma - Coronavirus, Coronavirus Infection | Phase 2 | Completed | Universidad del Rosario | 10 | 2020-05-01 | 2020-08-17 |
| A Study of a Candidate COVID-19 Vaccine (COV001) ChAdOx1 nCoV-19, MenACWY, ChAdOx1 nCoV-19 full boost - Coronavirus | Phase 1 / Phase 2 | Completed | University of Oxford | 1077 | 2020-04-23 | 2025-09-03 |
| CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients Convalescent Plasma, Saline solution - COVID-19, Coronavirus | Phase 2 | Completed | NYU Langone Health | 941 | 2020-04-17 | 2023-01-26 |
Showing 20 of 24. Sign in to see all of them.
Coronavirus Infections (24) · COVID-19 (22) · Severe Acute Respiratory Syndrome (6) · Pneumonia (2) · Acute Lung Injury (1) · Communicable Diseases (1) · Convalescence (1) · Coronaviridae Infections (1) · Lung Diseases, Interstitial (1) · Nidovirales Infections (1) · Pneumonia, Viral (1) · RNA Virus Infections (1) · Respiratory Distress Syndrome (1) · Virus Diseases (1)
Infections (24) · Respiratory Tract Diseases (24) · Respiratory Tract Infections (24) · Coronaviridae Infections (23) · Nidovirales Infections (23) · RNA Virus Infections (23) · Virus Diseases (23) · Lung Diseases (22) · Pneumonia, Viral (21) · Pneumonia (20) · Disease Attributes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Lung Injury (1) · Respiration Disorders (1)
COVID-19 Serotherapy (2) · ChAdOx1 nCoV-19 (2) · Hydroxychloroquine (2) · Standard of Care (2) · Acetaminophen (1) · Ascorbic Acid (1) · CVnCoV COVID-19 vaccine (1) · Calcifediol (1) · Endothelium-Dependent Relaxing Factors (1) · Fluvoxamine (1) · Hepatitis A Vaccines (1) · MenACWY (1) · Meningococcal Vaccines (1) · PRIME protocol (1) · Pneumococcal Vaccines (1)
Universidad del Rosario (2) · University of Oxford (2) · Apellis Pharmaceuticals, Inc. (1) · CureVac (1) · Henry Ford Health System (1) · Imperial College London (1) · Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus (1) · Johns Hopkins University (1) · MGC Pharmaceuticals d.o.o (1) · Massachusetts General Hospital (1) · Medical University of South Carolina (1) · NYU Langone Health (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · OPKO Health, Inc. (1) · ProgenaBiome (1)
United States (15) · Brazil (3) · United Kingdom (3) · Colombia (2) · Argentina (1) · Belarus (1) · Canada (1) · Guatemala (1) · India (1) · Israel (1) · Mexico (1) · Panama (1) · Peru (1) · Philippines (1) · Puerto Rico (1)
Andrew Pollard, Prof (2) · Juan M Anaya Cabrera, MD, PhD (2) · Adam Spivak, MD (1) · Akhtar Ashfaq, MD FACP FASN (1) · Andrei Y Hancharou, Dr. (1) · David Smith, MD, MAS (1) · Eduard A Dotsenko, Dr., prof. (1) · Eric J Lenze, MD (1) · Geneva Tatem, MD (1) · Latha Dulipsingh, MD (1) · Lorenzo Berra, MD (1) · Mark S George, MD (1) · Mila B Ortigoza, MD, PhD (1) · Miriam Treggiari, MD (1) · Natalia G Antonevich, Dr. (1)
PMID 33306989, PMID 33617777, PMID 34480858, PMID 32511534, PMID 32702298, PMID 32883593, PMID 32951151, PMID 33044747, PMID 33180097, PMID 33220855, PMID 33240091, PMID 33335322, PMID 33335323, PMID 33783269, PMID 33798499, PMID 33845867, PMID 34013969, PMID 34153264, PMID 34473343, PMID 34901997, PMID 34931202, PMID 34981077, PMID 35192543, PMID 35579509, PMID 35713300, PMID 35761219, PMID 35765566, PMID 35793677, PMID 35797235, PMID 35995785, PMID 36002874, PMID 36210483, PMID 36289399, PMID 36301549, PMID 36378539, PMID 36467293, PMID 36661240, PMID 36734509, PMID 36802755, PMID 37068272, PMID 37099295, PMID 37138460, PMID 37162745, PMID 37279602, PMID 37650230, PMID 37650232, PMID 37650233, PMID 37650236, PMID 37855026, PMID 39018444
U54GM104941 (1)